JP2013518049A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013518049A5 JP2013518049A5 JP2012550135A JP2012550135A JP2013518049A5 JP 2013518049 A5 JP2013518049 A5 JP 2013518049A5 JP 2012550135 A JP2012550135 A JP 2012550135A JP 2012550135 A JP2012550135 A JP 2012550135A JP 2013518049 A5 JP2013518049 A5 JP 2013518049A5
- Authority
- JP
- Japan
- Prior art keywords
- lactide
- intraluminal implant
- therapeutic agent
- implant according
- poly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007943 implant Substances 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 7
- 229940124597 therapeutic agent Drugs 0.000 claims 7
- 229920001244 Poly(D,L-lactide) Polymers 0.000 claims 5
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims 3
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical group CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 claims 3
- 229960002470 bimatoprost Drugs 0.000 claims 3
- 238000002513 implantation Methods 0.000 claims 3
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 210000002159 anterior chamber Anatomy 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 230000004410 intraocular pressure Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29766010P | 2010-01-22 | 2010-01-22 | |
| US61/297,660 | 2010-01-22 | ||
| PCT/US2011/021971 WO2011091205A2 (en) | 2010-01-22 | 2011-01-21 | Intracameral sustained release therapeutic agent implants |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013518049A JP2013518049A (ja) | 2013-05-20 |
| JP2013518049A5 true JP2013518049A5 (OSRAM) | 2014-03-06 |
| JP5809169B2 JP5809169B2 (ja) | 2015-11-10 |
Family
ID=43795202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012550135A Active JP5809169B2 (ja) | 2010-01-22 | 2011-01-21 | 治療薬持続放出型腔内インプラント |
Country Status (12)
| Country | Link |
|---|---|
| US (8) | US8647659B2 (OSRAM) |
| EP (3) | EP3320892A1 (OSRAM) |
| JP (1) | JP5809169B2 (OSRAM) |
| KR (4) | KR102337046B1 (OSRAM) |
| CN (2) | CN107184544A (OSRAM) |
| AU (1) | AU2011207281B2 (OSRAM) |
| BR (1) | BR112012018134B1 (OSRAM) |
| CA (1) | CA2787514C (OSRAM) |
| DK (2) | DK3085358T3 (OSRAM) |
| ES (2) | ES2561083T3 (OSRAM) |
| RU (1) | RU2565445C2 (OSRAM) |
| WO (1) | WO2011091205A2 (OSRAM) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
| US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
| US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
| US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
| US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US8673341B2 (en) * | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
| US8968396B2 (en) | 2007-07-23 | 2015-03-03 | Powervision, Inc. | Intraocular lens delivery systems and methods of use |
| US20170360609A9 (en) | 2007-09-24 | 2017-12-21 | Ivantis, Inc. | Methods and devices for increasing aqueous humor outflow |
| US20100247606A1 (en) * | 2009-03-25 | 2010-09-30 | Allergan, Inc. | Intraocular sustained release drug delivery systems and methods for treating ocular conditions |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| AU2010249683B2 (en) | 2009-05-18 | 2015-06-25 | Glaukos Corporation | Drug eluting ocular implant |
| CN102481404B (zh) | 2009-07-09 | 2014-03-05 | 伊万提斯公司 | 眼部植入物 |
| EP2451375B1 (en) | 2009-07-09 | 2018-10-03 | Ivantis, Inc. | Single operator device for delivering an ocular implant |
| ES2561083T3 (es) * | 2010-01-22 | 2016-02-24 | Allergan, Inc. | Implantes intracamerales de agentes terapéuticos de liberación sostenida |
| EP2539351B1 (en) | 2010-02-23 | 2017-07-12 | PowerVision, Inc. | Fluid for accommodating intraocular lenses |
| EP2654715B1 (en) | 2010-11-24 | 2017-01-25 | Dose Medical Corporation | Drug eluting ocular implant |
| EP3494959A3 (en) | 2011-04-29 | 2019-09-11 | Allergan, Inc. | Sustained release latanoprost implant |
| US10245178B1 (en) * | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
| US8657776B2 (en) | 2011-06-14 | 2014-02-25 | Ivantis, Inc. | Ocular implants for delivery into the eye |
| US8663150B2 (en) | 2011-12-19 | 2014-03-04 | Ivantis, Inc. | Delivering ocular implants into the eye |
| US9358156B2 (en) | 2012-04-18 | 2016-06-07 | Invantis, Inc. | Ocular implants for delivery into an anterior chamber of the eye |
| US20150272877A1 (en) * | 2012-10-26 | 2015-10-01 | Allergan, Inc. | Ketorolac-containing sustained release drug delivery systems |
| WO2014066653A1 (en) * | 2012-10-26 | 2014-05-01 | Allergan, Inc. | Ketorolac-containing sustained release intraocular drug delivery systems |
| US10617558B2 (en) | 2012-11-28 | 2020-04-14 | Ivantis, Inc. | Apparatus for delivering ocular implants into an anterior chamber of the eye |
| WO2014159576A1 (en) * | 2013-03-14 | 2014-10-02 | Allergan, Inc. | Alpha-2 adrenergic agonist for treating intraocular pressure and ocular diseases through intravitreal and intracameral routes |
| US9289413B2 (en) * | 2013-03-15 | 2016-03-22 | Allergan, Inc. | Prostamide-containing intraocular implant |
| EP2967842B1 (en) | 2013-03-15 | 2020-11-04 | Alcon Inc. | Method of reconfiguring an intraocular lens for delivery to a delivery device |
| CA2908645A1 (en) | 2013-04-01 | 2014-10-09 | Allergan, Inc. | Microsphere drug delivery system for sustained intraocular release |
| EP3351239B1 (en) * | 2013-10-31 | 2020-04-01 | Allergan, Inc. | Prostamide-containing intraocular implants and methods of use thereof |
| CN106132397A (zh) * | 2013-12-06 | 2016-11-16 | 恩维希亚治疗股份有限公司 | 用于治疗眼部疾病的前房内植入物 |
| CA2950187A1 (en) | 2014-05-29 | 2015-12-03 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| US10709547B2 (en) | 2014-07-14 | 2020-07-14 | Ivantis, Inc. | Ocular implant delivery system and method |
| MY178327A (en) | 2014-09-06 | 2020-10-08 | Integral Biosystems Llc | Methods and biocompatible compositions to achieve sustained drug release in the eye |
| EP4566638A3 (en) * | 2015-05-29 | 2025-08-27 | Allergan, Inc. | Implant for treatment of an ocular condition |
| KR102643821B1 (ko) * | 2015-06-06 | 2024-03-07 | 클라우드브레이크 테라퓨틱스, 엘엘씨 | 익상편을 치료하기 위한 조성물 및 방법 |
| ES2962607T3 (es) | 2015-08-14 | 2024-03-20 | Alcon Inc | Implante ocular con sensor de presión |
| US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
| WO2017053885A1 (en) | 2015-09-25 | 2017-03-30 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
| US11458041B2 (en) | 2015-10-08 | 2022-10-04 | Ocular Therapeutix, Inc. | Punctal plug and bioadhesives |
| WO2017106517A1 (en) * | 2015-12-15 | 2017-06-22 | Ivantis, Inc. | Ocular implant and delivery system |
| PT109154B (pt) * | 2016-02-12 | 2019-11-05 | Univ De Coimbra | Tecnologia não-invasiva de inserto ocular para libertação controlada de fármacos |
| EP3442479A1 (en) | 2016-04-20 | 2019-02-20 | Harold Alexander Heitzmann | Bioresorbable ocular drug delivery device |
| MX2018014868A (es) | 2016-06-02 | 2019-09-13 | Cloudbreak Therapeutics Llc | Composiciones y metodos de uso de nintedanib para mejorar el exito de la cirugia del glaucoma. |
| KR102520771B1 (ko) | 2016-09-23 | 2023-04-12 | 인셉트, 엘엘씨 | 전안방내 약물 전달 데포 |
| CN110475543B (zh) * | 2016-09-30 | 2023-07-25 | 马缇医疗股份有限公司 | 眼用药物持续释放制剂及其用途 |
| WO2018169967A1 (en) | 2017-03-14 | 2018-09-20 | Allergan, Inc. | Acorafloxacin in treating ocular infections |
| US10765629B2 (en) | 2017-07-25 | 2020-09-08 | Allergan, Inc. | Solid complex, preparations and uses thereof |
| US20190192341A1 (en) * | 2017-11-09 | 2019-06-27 | Allergan, Inc. | Sustained-Release Implants for Lowering Intraocular Pressure with Extended Duration of Effect |
| CA3207829A1 (en) | 2018-02-22 | 2019-08-29 | Alcon Inc. | Ocular implant and delivery system |
| CN112566622A (zh) * | 2018-06-19 | 2021-03-26 | 细胞疗法有限责任公司 | 用于治疗青光眼或高眼压症的包含眼内压降低剂、cnp化合物、npr-b化合物、tie-2激动剂或神经营养剂的缓释药物递送系统 |
| US11077053B2 (en) | 2018-08-21 | 2021-08-03 | Allergan, Inc. | Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia |
| KR20210047323A (ko) | 2018-08-21 | 2021-04-29 | 알러간, 인코포레이티드 | 시력 개선을 위한 알파-2-아드레날린성 수용체 효능제의 용도 |
| US20200069575A1 (en) * | 2018-08-30 | 2020-03-05 | Yunxiang Liu | Ophthalmic formulations, process for preparing the same and method for administering the same |
| DK3861985T3 (da) | 2020-02-06 | 2023-07-24 | Ocular Therapeutix Inc | Sammensætninger og fremgangsmåder til behandling af øjensygdomme |
| MX2022010317A (es) | 2020-02-20 | 2023-01-24 | Allergan Inc | Composiciones farmaceuticas de agonistas de receptores alpha-2-adrenergicos y su uso para mejorar la vision. |
| US20210260042A1 (en) | 2020-02-20 | 2021-08-26 | Allergan, Inc. | Alpha-2-adrenergic receptor agonists for reducing redness and increasing whiteness in eyes and other ophthalmic purposes |
| CN115768385A (zh) | 2020-04-27 | 2023-03-07 | 视觉治疗股份有限公司 | 治疗过敏性结膜炎的方法 |
| US11540940B2 (en) | 2021-01-11 | 2023-01-03 | Alcon Inc. | Systems and methods for viscoelastic delivery |
| CN115607741B (zh) * | 2022-09-08 | 2023-11-24 | 西安德诺海思医疗科技有限公司 | 一种青光眼外科手术用复合生物材料及其应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3749776A (en) * | 1970-08-28 | 1973-07-31 | Allergan Pharma | Method for blocking prostaglandin activity |
| US5166331A (en) * | 1983-10-10 | 1992-11-24 | Fidia, S.P.A. | Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same |
| US6309669B1 (en) * | 1984-03-16 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix |
| US4997652A (en) * | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
| US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| US5516522A (en) | 1994-03-14 | 1996-05-14 | Board Of Supervisors Of Louisiana State University | Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same |
| US5612027A (en) * | 1995-04-18 | 1997-03-18 | Galin; Miles A. | Controlled release of miotic and mydriatic drugs in the anterior chamber |
| US5972326A (en) * | 1995-04-18 | 1999-10-26 | Galin; Miles A. | Controlled release of pharmaceuticals in the anterior chamber of the eye |
| US6369116B1 (en) | 1995-06-02 | 2002-04-09 | Oculex Pharmaceuticals, Inc. | Composition and method for treating glaucoma |
| US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US5994309A (en) | 1997-07-25 | 1999-11-30 | Angstrom Pharmaceuticals, Inc. | Anti-invasive and anti-angiogenic compositions and methods |
| US6726918B1 (en) | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
| PE20020146A1 (es) | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
| CN100569291C (zh) | 2000-07-14 | 2009-12-16 | 阿勒根公司 | 含有α-2肾上腺素能激动剂的组合物 |
| AU2002248284A1 (en) | 2000-11-01 | 2002-08-06 | Allergan, Inc. | Compositions for treatment of ocular neovascularization |
| ATE306951T1 (de) | 2000-11-29 | 2005-11-15 | Allergan Inc | Verhinderung von transplantatabstossung im auge |
| GB0122318D0 (en) | 2001-09-14 | 2001-11-07 | Novartis Ag | Organic compounds |
| AU2002330085A1 (en) * | 2001-09-24 | 2003-05-26 | Mount Sinai School Of Medicine | Methods and compositions for therapeutic treatment of cathepsin k complex-mediated disorders |
| WO2004043432A2 (en) * | 2002-11-06 | 2004-05-27 | Alza Corporation | Controlled release depot formulations |
| US20040253293A1 (en) * | 2003-06-16 | 2004-12-16 | Afshin Shafiee | Rate controlled release of a pharmaceutical agent in a biodegradable device |
| US20070224278A1 (en) * | 2003-11-12 | 2007-09-27 | Lyons Robert T | Low immunogenicity corticosteroid compositions |
| US20050101582A1 (en) * | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
| US20090148527A1 (en) * | 2007-12-07 | 2009-06-11 | Robinson Michael R | Intraocular formulation |
| US20120283232A9 (en) * | 2003-11-12 | 2012-11-08 | Zhengjun Wang | Process for making a pharmaceutical composition |
| BRPI0506983A (pt) * | 2004-01-20 | 2007-07-03 | Allergan Inc | composições para terapia localizada dos olhos, compreendendo preferencialmente acetonida de triancinolona e ácido hialurÈnico |
| US8673341B2 (en) * | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
| US7993634B2 (en) * | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
| US7771742B2 (en) * | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| US8722097B2 (en) * | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
| US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| US7589057B2 (en) * | 2004-04-30 | 2009-09-15 | Allergan, Inc. | Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems |
| US7799336B2 (en) * | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US20060182781A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Methods for treating ocular conditions with cyclic lipid contraining microparticles |
| US20090082321A1 (en) * | 2007-09-21 | 2009-03-26 | Allergan, Inc. | Steroid containing drug delivery systems |
| US20070293873A1 (en) * | 2006-06-19 | 2007-12-20 | Allergan, Inc. | Apparatus and methods for implanting particulate ocular implants |
| US20080097335A1 (en) * | 2006-08-04 | 2008-04-24 | Allergan, Inc. | Ocular implant delivery assemblies |
| US8969415B2 (en) * | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| US8846073B2 (en) | 2006-12-19 | 2014-09-30 | Allergan, Inc. | Low temperature processes for making cyclic lipid implants for intraocular use |
| US8231892B2 (en) * | 2007-05-24 | 2012-07-31 | Allergan, Inc. | Biodegradable drug delivery system |
| US20110152328A1 (en) | 2008-04-16 | 2011-06-23 | Whitcup Scott M | Combination Therapy For Glaucoma |
| EP2296621A1 (en) | 2008-05-20 | 2011-03-23 | Yale University | Biodegradable sustained-release polymeric microparticulates comprising a hydrophobic drug and determined for ophthalmic use |
| US20100104654A1 (en) * | 2008-10-27 | 2010-04-29 | Allergan, Inc. | Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof |
| US9095506B2 (en) | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
| US8545554B2 (en) * | 2009-01-16 | 2013-10-01 | Allergan, Inc. | Intraocular injector |
| US20100247606A1 (en) * | 2009-03-25 | 2010-09-30 | Allergan, Inc. | Intraocular sustained release drug delivery systems and methods for treating ocular conditions |
| ES2561083T3 (es) * | 2010-01-22 | 2016-02-24 | Allergan, Inc. | Implantes intracamerales de agentes terapéuticos de liberación sostenida |
| WO2011109384A2 (en) | 2010-03-02 | 2011-09-09 | Allergan, Inc. | Biodegradable polymers for lowering intraocular pressure |
| EP2585071A1 (en) * | 2010-06-28 | 2013-05-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pharmaceutical composition for use in the treatment of glaucoma |
| EP3494959A3 (en) | 2011-04-29 | 2019-09-11 | Allergan, Inc. | Sustained release latanoprost implant |
-
2011
- 2011-01-21 ES ES11701723.6T patent/ES2561083T3/es active Active
- 2011-01-21 EP EP17001789.1A patent/EP3320892A1/en not_active Withdrawn
- 2011-01-21 EP EP11701723.6A patent/EP2525776B1/en active Active
- 2011-01-21 AU AU2011207281A patent/AU2011207281B2/en active Active
- 2011-01-21 EP EP15191632.7A patent/EP3085358B1/en active Active
- 2011-01-21 RU RU2012133880/15A patent/RU2565445C2/ru active
- 2011-01-21 JP JP2012550135A patent/JP5809169B2/ja active Active
- 2011-01-21 BR BR112012018134-3A patent/BR112012018134B1/pt active IP Right Grant
- 2011-01-21 KR KR1020207017535A patent/KR102337046B1/ko not_active Expired - Fee Related
- 2011-01-21 CN CN201710411369.5A patent/CN107184544A/zh active Pending
- 2011-01-21 KR KR1020207007048A patent/KR102126007B1/ko active Active
- 2011-01-21 ES ES15191632.7T patent/ES2658175T3/es active Active
- 2011-01-21 CA CA2787514A patent/CA2787514C/en active Active
- 2011-01-21 US US13/011,467 patent/US8647659B2/en active Active
- 2011-01-21 DK DK15191632.7T patent/DK3085358T3/en active
- 2011-01-21 CN CN2011800149985A patent/CN102821753A/zh active Pending
- 2011-01-21 KR KR1020127021839A patent/KR101911960B1/ko not_active Expired - Fee Related
- 2011-01-21 KR KR1020187030084A patent/KR20180117211A/ko not_active Ceased
- 2011-01-21 DK DK11701723.6T patent/DK2525776T3/en active
- 2011-01-21 WO PCT/US2011/021971 patent/WO2011091205A2/en not_active Ceased
-
2013
- 2013-09-19 US US14/031,657 patent/US9061065B2/en active Active
-
2015
- 2015-06-22 US US14/746,438 patent/US9504696B2/en active Active
-
2016
- 2016-11-28 US US15/362,197 patent/US10278919B2/en active Active
-
2019
- 2019-05-06 US US16/403,965 patent/US20190254965A1/en not_active Abandoned
- 2019-12-18 US US16/718,640 patent/US20200121593A1/en not_active Abandoned
-
2020
- 2020-10-23 US US17/079,148 patent/US20210169780A1/en not_active Abandoned
-
2023
- 2023-08-21 US US18/236,215 patent/US20240148643A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013518049A5 (OSRAM) | ||
| RU2012133880A (ru) | Внутрикамерные имплантаты с пролонгированным высвобождением терапевтического агента | |
| US9943404B2 (en) | Intraocular cell migration inhibition system | |
| JP2021502366A5 (OSRAM) | ||
| US10548766B2 (en) | Biocompatible biodegradable intraocular implant system | |
| US8551167B2 (en) | Intraocular implant cell migration inhibition system | |
| SI3062775T1 (en) | Intraocular implants containing prostamide and methods for their use | |
| Argento et al. | Optic capture of the AcrySof intraocular lens in pediatric cataract surgery | |
| McNab | Hydroxyapatite orbital implants Experience with 100 cases | |
| EP3104851A1 (en) | Pharmacological ophthalmic composition for use in the correction of presbyopia and its administration | |
| Lee et al. | The efficacy of an acrylic intraocular lens surface modified with polyethylene glycol in posterior capsular opacification | |
| Pinsard et al. | Neodymium: YAG laser treatment of late capsular block syndrome | |
| CN212662027U (zh) | 一种人工晶状体的环形囊袋 | |
| Rosen et al. | Endocapsular cataract extraction | |
| Akaishi et al. | Multifocal intraocular lens optic anteriorization capture to correct residual refractive error | |
| Ozcan et al. | Scleral fixation–Where are we | |
| Shrestha | Cataract surgery in children: Controversies and practices | |
| Bylsma | Correction of Keratometric Astigmatism: Staar Toric IOL Refractive Lens Surgery | |
| Trivedi et al. | Primary intraocular lens implantation in infantile cataract surgery | |
| Bhullar et al. | July consultation# 4 | |
| Foam-Covered | Case 160: Double Folds | |
| Falavarjani et al. | Fibrin glue–assisted sutureless scleral fixation | |
| RU2339352C1 (ru) | Способ имплантации заднекамерной интраокулярной линзы | |
| Masnec et al. | Cataract Surgery | |
| Choi et al. | Pigmented-membrane formation on acrylic intraocular lenses after phacoemulsification |